Vyriad Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
90
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$25M
- Investors
-
8
Vyriad General Information
Description
Developer of targeted genetic therapies using engineered viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells. This technology facilitates oncolytic virotherapy, in vivo gene therapies, and editing applications, enabling clinicians with oncolytic viruses as monotherapies and in combination with immune-oncology drugs in multiple cancer indications.
Contact Information
Website
www.vyriad.comCorporate Office
- 2900 37th Street Northwest
- Building 110
- Rochester, MN 55901
- United States
Corporate Office
- 2900 37th Street Northwest
- Building 110
- Rochester, MN 55901
- United States
Vyriad Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series B1) | 23-Dec-2025 | $25M | Completed | Clinical Trials - Phase 2 | ||
| 9. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 8. Later Stage VC (Series B) | 17-May-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Early Stage VC (Series B) | 14-Nov-2019 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 18-Sep-2018 | Completed | Pre-Clinical Trials | |||
| 5. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 4. Grant | 13-Apr-2018 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 12-Apr-2017 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 01-Jan-2017 | $10M | $10M | Completed | Pre-Clinical Trials | |
| 1. Merger of Equals | 18-Mar-2016 | Completed | Pre-Clinical Trials |
Vyriad Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 4,087,847 | $0.000100 | $2.51 | $2.51 | 1x | $2.51 | 5.89% |
Vyriad Comparisons
Industry
Financing
Details
Vyriad Competitors (4)
One of Vyriad’s 4 competitors is Umoja Biopharma, a Venture Capital-Backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Umoja Biopharma | Venture Capital-Backed | Seattle, WA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Sana Biotechnology | Formerly VC-backed | Seattle, WA | ||||
| Kelonia | Formerly VC-backed | Boston, MA |
Vyriad Patents
Vyriad Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236565-A1 | Oligomerization of glycoproteins and uses thereof | Pending | 07-May-2025 | ||
| WO-2026236521-A1 | Viral vectors, components thereof, and uses of the vectors and components thereof for production and delivery of a payload | Pending | 07-May-2025 | ||
| WO-2026207502-A1 | Immunological cells, uses thereof, and methods for in vivo delivery of chimeric antigen receptors | Pending | 27-Mar-2025 | ||
| WO-2026187925-A1 | Rous sarcoma virus virus-like particles, components thereof, and uses | Pending | 04-Mar-2025 | ||
| WO-2026182903-A1 | Methods and materials for treating cancer | Pending | 26-Feb-2025 | A61K39/395 |
Vyriad Signals
Vyriad Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mayo Clinic Ventures | Corporate Venture Capital | Minority | ||
| Mirae Asset Capital | Venture Capital | Minority | ||
| Stine Seed Company | Corporation | Minority | ||
| Regeneron Pharmaceuticals | Corporation | Minority | ||
| Southeast Minnesota Capital Fund | Venture Capital | Minority |
Vyriad Acquisitions (2)
Vyriad’s most recent deal was a Merger of Equals with Magnis Therapeutics. The deal was made on 18-Mar-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Magnis Therapeutics | 18-Mar-2016 | Merger of Equals | Biotechnology | ||
| Omnis Pharma | 18-Mar-2016 | Merger of Equals | Biotechnology |
Vyriad FAQs
-
When was Vyriad founded?
Vyriad was founded in 2015.
-
Where is Vyriad headquartered?
Vyriad is headquartered in Rochester, MN.
-
What is the size of Vyriad?
Vyriad has 90 total employees.
-
What industry is Vyriad in?
Vyriad’s primary industry is Biotechnology.
-
Is Vyriad a private or public company?
Vyriad is a Private company.
-
What is the current valuation of Vyriad?
The current valuation of Vyriad is .
-
What is Vyriad’s current revenue?
The current revenue for Vyriad is .
-
How much funding has Vyriad raised over time?
Vyriad has raised $113M.
-
Who are Vyriad’s investors?
Mayo Clinic Ventures, Mirae Asset Capital, Stine Seed Company, Regeneron Pharmaceuticals, and Southeast Minnesota Capital Fund are 5 of 8 investors who have invested in Vyriad.
-
Who are Vyriad’s competitors?
Umoja Biopharma, Intellia Therapeutics, Sana Biotechnology, and Kelonia are competitors of Vyriad.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process